Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common stock, $.01 par value per share
-
Shares outstanding
-
46,791,479
-
Total 13F shares
-
50,595,124
-
Share change
-
+708,329
-
Total reported value
-
$5,040,192,796
-
Put/Call ratio
-
131%
-
Price per share
-
$99.66
-
Number of holders
-
263
-
Value change
-
+$54,162,521
-
Number of buys
-
124
-
Number of sells
-
165
Institutional Holders of HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) as of Q1 2020
As of 31 Mar 2020,
HAEMONETICS CORP - Common stock, $.01 par value per share (HAE) was held by
263 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,595,124 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, Capital Research Global Investors, Neuberger Berman Group LLC, WELLINGTON MANAGEMENT GROUP LLP, RENAISSANCE TECHNOLOGIES LLC, Jackson Square Partners, LLC, FMR LLC, STATE STREET CORP, and HealthCor Management, L.P..
This page lists
263
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.